Lucida Medical
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $14M
Investors
- 4
About Lucida Medical
Based in the UK, Lucida Medical Ltd develops advanced AI systems aimed at improving the detection and diagnosis of prostate cancer through innovative MRI technology. Based in Cambridge, UK, founded in 2019, by its co-founder Antony Rix and Evis Sala, Lucida Medical Ltd focuses on enhancing cancer diagnosis through its AI-driven solutions. Antony Rix, who also serves as the CEO, bringing prior experience in leading tech-driven healthcare innovations. Lucida Medical specializes in developing advanced artificial intelligence (AI) systems designed to enhance the detection and diagnosis of prostate cancer through MRI technology. The company's flagship product, Pi™, is engineered to operate at the level of expert radiologists, effectively processing multi-centre data from various MRI scanner vendors and models. This AI solution has been clinically validated, demonstrating a 95% sensitivity and 67% specificity in identifying clinically significant prostate cancers. Lucida Medical's technology is primarily utilized by healthcare providers within the NHS and private hospital systems across the United Kingdom, as well as in international markets. These systems aim to streamline the patient care pathway by expediting cancer diagnosis, thereby allowing clinicians to offer timely treatment options, such as same-day biopsies, enhancing the overall efficiency of prostate cancer management. Lucida Medical generates revenue through B2B partnerships with healthcare institutions, specifically NHS hospitals and private clinics, which integrate the Pi™ system into their diagnostic workflows. The revenue model includes subscription agreements for ongoing access to the AI technology and potential licensing fees associated with utilizing their proprietary software in clinical settings. As healthcare institutions adopt Pi™, they incur transactional costs related to software implementation, training, and ongoing support services. These financial arrangements facilitate the delivery of innovative diagnostic solutions directly to healthcare providers, thereby reinforcing the value of AI in enhancing diagnostic accuracy and operational efficiency in prostate cancer care.
Who invested in Lucida Medical
4 investors across 2 rounds
See all investors in Lucida Medical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lucida Medical
Who invested in Lucida Medical?
Lucida Medical has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lucida Medical raised?
Lucida Medical has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Lucida Medical last raise money?
Lucida Medical's most recent round on record is a Series A, in Mar 2026.
What does Lucida Medical do?
Based in the UK, Lucida Medical Ltd develops advanced AI systems aimed at improving the detection and diagnosis of prostate cancer through innovative MRI technology.
Where is Lucida Medical headquartered?
Lucida Medical is headquartered in Cambridge, UK.
Which VCs invest in companies like Lucida Medical?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back medical devices & equipment companies at Lucida Medical's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Lucida Medical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.